insulin (oral, Oshadi Icp formulation)

Oshadi ICP is an oral formulation of human insulin developed by Oshadi Drug Administration for the treatment of type 1 diabetes mellitus. The drug combines insulin, proinsulin, and C-peptide within a proprietary carrier designed to enable absorption of these proteins from the gastrointestinal tract while maintaining their full structure[3][5][8]. This approach aims to provide a non-injectable alternative for insulin therapy, potentially improving patient compliance and mimicking physiological hepatic delivery more closely than subcutaneous injections[5][8]. Clinical studies have shown that Oshadi ICP is well tolerated with no significant adverse events or safety concerns reported. Efficacy data indicate that it can lower blood glucose concentrations in patients with type 1 diabetes while allowing for reduced doses of rapid acting injected insulin[7]. The mechanism of action involves stimulation of ornithine decarboxylase, phosphokinase, and protein tyrosine kinase pathways[3].

Brand names

Oshadi ICP

Other names

oral insulin (Oshadi Drug Administration)Icp-insulinproinsulin and C-peptide in Oshadi carrier